Cover Image for Bits in Bio and Nucleate Present: What Is a Dead Drug Program Worth? AI from Preclinical to the Clinic
Cover Image for Bits in Bio and Nucleate Present: What Is a Dead Drug Program Worth? AI from Preclinical to the Clinic
8 Going

Bits in Bio and Nucleate Present: What Is a Dead Drug Program Worth? AI from Preclinical to the Clinic

Hosted by Aaron Blotnick & 4 others
Registration
Welcome! To join the event, please register below.
About Event

β€‹πŸ’€ What is a dead drug program worth?

​AI companies are now buying data from failed drug programs: Phase 1 readouts, patient-level biomarkers, even the slide decks explaining why a program stopped.

​With discovery quickly being priced to zero, the next hurdle for AI is preclinical and clinical development. The data to get there is sitting in shelved programs.

​But how will AI actually help?

​We're bringing together three experts across the preclinical, clinical, and post-clinical sides of drug development to talk about where AI is already changing decisions.

​πŸ§ͺ Preclinical
The FDA has started phasing out some animal testing requirements. What can AI and human-cell models actually replace before IND, and what still needs an animal?

​πŸ₯ Clinical
Digital twins that let trials run with fewer patients, using a method regulators have already accepted.

β€‹πŸ“Š Post-clinical
Turning the trial data a company already owns into better patient selection and the next study design.

​The questions: What data actually makes these models better? Who owns it? And what is a dead program worth?

β€‹πŸŽ€ Speakers

​Roopa Ramamoorthi, PhD, PMP | Director, Catalyst Program and InVent Fund, UCSF

  • ​Leads UCSF's Catalyst Program and InVent Fund, where she has spent 10 years

  • ​Previously led WIPO Re:Search partnering at BioVentures for Global Health, matching researchers with pharma resources for neglected diseases, TB and malaria

  • ​Former Senior Scientist at Bayer, with work spanning purification development, viral validation, and external collaborations

  • ​USPTO registered patent agent and PMP certified project manager

​Jon Walsh, PhD | Co-founder and CSO, Unlearn.AI

  • ​Physicist, with a PhD from the University of Washington and a postdoc at UC Berkeley

  • ​Co-founded Unlearn in 2017

  • ​Leads its work bringing digital twins into drug development and through regulators

​Elena Cassidy, PhD | CEO and Co-founder, Omabit

  • ​Molecular biology PhD, Moscow State University

  • ​Co-developed a 9-cancer early detection assay at Avida Biomed (acquired by Agilent)

  • ​Led a rare disease assay at Natera

​Moderator: Yizi Mao, PhD | Co-Managing Director, Nucleate Bay Area

  • ​Postdoc at UC Berkeley, building high-throughput single-cell multi-omics sequencing methods

  • ​Previously a postdoc at the University of Washington in DNA sequencing technology

  • ​PhD in Biochemistry, University of Nebraska-Lincoln

β€‹πŸ—“οΈ Schedule

  • ​6:00 PM | Doors open, food and drinks πŸ•

  • ​6:45 PM | Welcome from Bits in Bio SF

  • ​6:50 PM | Panel

  • ​7:35 PM | Audience Q&A

  • ​7:50 PM | Networking

  • ​8:30 PM | Close

​πŸ‘₯ Who should come
Scientists, engineers, founders, and investors working in:

  • ​Preclinical development, safety and tox

  • ​Translational science and clinical development

  • ​Biostatistics and AI for drug development

β€‹βš οΈ Space is limited. Registration requires approval.

β€‹πŸ™ Thank you
Fenwick for hosting. Fenwick is a law firm serving technology and life sciences companies.
Nucleate Bay Area for helping bring this together.

β€‹πŸ§¬ About Bits in Bio
Bits in Bio is a community connecting the bioeconomy across software, AI, and biology, with more than 12,000 members. We host meetups, Q&As with industry leaders, hackathons, and networking events in chapters around the world.

Location
Fenwick & West
One Front Street, Front St Floors 31-33, San Francisco, CA 94111, USA
8 Going